Drug combinations and uses in treating a coughing condition

Patent metadata

Field	Value
Publication number	US-9308211-B2
Application number	US-201414287015-A
Country	US
Kind code	B2
Filing date	May 24, 2014
Priority date	Jun 16, 2009
Publication date	Apr 12, 2016
Grant date	Apr 12, 2016

Abstract

The present specification discloses compositions comprising a plurality of therapeutic compound having antitussive activity and methods and uses for treating a coughing condition with such compositions.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising 0.5 mg/mL to 10 mg/mL of Theobromine, 0.25 mg/mL to 5 mg/mL of Dextromethorphan, and 0.1 mg/mL to 5 mg/mL of Phenylephrine, wherein the pharmaceutical composition does not include an anti-histamine and wherein the therapeutically-effective amount of the theobromine is at most 250 mg/day.

2. The pharmaceutical composition according to claim 1 , wherein the composition comprises 0.5 mg/mL to 6 mg/mL of Theobromine, 0.5 mg/mL to 3 mg/mL of Dextromethorphan, and 0.1 mg/mL to 2 mg/mL of Phenylephrine.

3. The pharmaceutical composition according to claim 2 , wherein the composition comprises 1 mg/mL to 3 mg/mL of Theobromine, 1 mg/mL to 3 mg/mL of Dextromethorphan, and 0.1 mg/mL to 1 mg/mL of Phenylephrine.

4. The pharmaceutical composition according to claim 3 , wherein the composition comprises 2 mg/mL of Theobromine, 1 mg/mL of Dextromethorphan, and 0.5 mg/mL of Phenylephrine.

5. A method of treating cough, the method comprising the step of administering a therapeutically-effective amount of the pharmaceutical composition of claim 1 .

6. The method according to claim 5 , wherein the composition comprises 0.5 mg/mL to 6 mg/mL of Theobromine, 0.5 mg/mL to 3 mg/mL of Dextromethorphan, and 0.1 mg/mL to 2 mg/mL of Phenylephrine.

7. The method according to claim 6 , wherein the composition comprises 1 mg/mL to 3 mg/mL of Theobromine, 1 mg/mL to 3 mg/mL of Dextromethorphan, and 0.1 mg/mL to 1 mg/mL of Phenylephrine.

8. The method according to claim 7 , wherein the composition comprises 2 mg/mL of Theobromine, 1 mg/mL of Dextromethorphan, and 0.5 mg/mL of Phenylephrine.

9. The method according to claim 5 , wherein the therapeutically-effective amount of the pharmaceutical composition comprises between 40 mg/day and 300 mg/day of Theobromine, 10 mg/day and 150 mg/day of Dextromethorphan, and 5 mg/day and 75 mg/day of Phenylephrine.

10. The method according to claim 9 , wherein the therapeutically-effective amount of the pharmaceutical composition comprises between 60 mg/day and 240 mg/day of Theobromine, 30 mg/day and 120 mg/day of Dextromethorphan, and 15 mg/day and 60 mg/day of Phenylephrine.

Assignees

• Infirst Healthcare Ltd

Inventors

• Brew John
• Bannister Robin Mark

Classifications

• A61K31/485

  Morphinan derivatives, e.g. morphine, codeine · CPC title

• A61K31/522 Primary

  having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/137

  Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title